BioLineRx $BLRX started a Phase 2a study, COMBAT, evaluating a lead product candidate BL-8040 and Merck's $MRK KEYTRUDA (pembrolizumab), meant for curing metastatic pancreatic adenocarcinoma. The 30-subject open-label, single-arm trial will assess the clinical efficacy, safety and tolerability of the lead candidate. The study is being performed under the companies' January immunotherapy collaboration.